Levocetirizine dihydrochloride

Levocetirizine Dihydrochloride is the dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. Additionally, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Xyzal, (R)-Cetirizine dihydrochloride, Levocetirizine hydrochloride and Levocetirizine HCl. Its PubChem CID is 9955977.

CAS No 130018-87-0
Molecular Formula C21H27Cl3N2O3
Molecular Weight 461.80 g/mol
Synonyms 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride

Frequently Asked Questions